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Introduction
Myocardial infarction (MI) can be recognised by clinical
features, including electrocardiographic (ECG) findings, ele-
vated values of biochemical markers (biomarkers) of myo-
cardial necrosis, and by imaging, or may be defined by
pathology. It is a major cause of death and disability world-
wide. MI may be the first manifestation of coronary artery
disease (CAD) or it may occur, repeatedly, in patients with
established disease. Information on MI rates can provide
useful information regarding the burden of CAD within and
across populations, especially if standardized data are col-
lected in a manner that distinguishes between incident and
recurrent events. From the epidemiological point of view, the
incidence of MI in a population can be used as a proxy for the
prevalence of CAD in that population. The term ‘myocardial
infarction’ may have major psychological and legal implica-
tions for the individual and society. It is an indicator of one of
the leading health problems in the world and it is an outcome
measure in clinical trials, observational studies and quality
assurance programmes. These studies and programmes re-
quire a precise and consistent definition of MI.
In the past, a general consensus existed for the clinical
syndrome designated as MI. In studies of disease prevalence,
the World Health Organization (WHO) defined MI from
symptoms, ECG abnormalities and cardiac enzymes. How-
ever, the development of ever more sensitive and myocardial
tissue-specific cardiac biomarkers and more sensitive imag-
ing techniques now allows for detection of very small
amounts of myocardial injury or necrosis. Additionally, the
management of patients with MI has significantly improved,
resulting in less myocardial injury and necrosis, in spite of a
similar clinical presentation. Moreover, it appears necessary
to distinguish the various conditions which may cause MI,
such as ‘spontaneous’ and ‘procedure-related’ MI. Accord-
ingly, physicians, other healthcare providers and patients
require an up-to-date definition of MI.
In 2000, the First Global MI Task Force presented a new
definition of MI, which implied that any necrosis in the
setting of myocardial ischaemia should be labelled as MI.1
These principles were further refined by the Second Global
MI Task Force, leading to the Universal Definition of
Myocardial Infarction Consensus Document in 2007, which
emphasized the different conditions which might lead to an
MI.2 This document, endorsed by the European Society of
Cardiology (ESC), the American College of Cardiology
Foundation (ACCF), the American Heart Association (AHA),
and the World Heart Federation (WHF), has been well
accepted by the medical community and adopted by the
WHO.3 However, the development of even more sensitive
assays for markers of myocardial necrosis mandates further
revision, particularly when such necrosis occurs in the setting
of the critically ill, after percutaneous coronary procedures or
after cardiac surgery. The Third Global MI Task Force has
continued the Joint ESC/ACCF/AHA/WHF efforts by inte-
grating these insights and new data into the current document,
which now recognizes that very small amounts of myocardial
2022 Circulation October 16, 2012
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injury or necrosis can be detected by biochemical markers
and/or imaging.
Pathological Characteristics of Myocardial
Ischaemia and Infarction
MI is defined in pathology as myocardial cell death due to
prolonged ischaemia. After the onset of myocardial isch-
aemia, histological cell death is not immediate, but takes a
finite period of time to develop—as little as 20 min, or less in
some animal models.4 It takes several hours before myocar-
dial necrosis can be identified by macroscopic or microscopic
post-mortem examination. Complete necrosis of myocardial
cells at risk requires at least 2–4 h, or longer, depending on
the presence of collateral circulation to the ischaemic zone,
persistent or intermittent coronary arterial occlusion, the
sensitivity of the myocytes to ischaemia, pre-conditioning,
and individual demand for oxygen and nutrients.2 The entire
process leading to a healed infarction usually takes at least
5–6 weeks. Reperfusion may alter the macroscopic and
microscopic appearance.
Biomarker Detection of Myocardial Injury
With Necrosis
Myocardial injury is detected when blood levels of sensitive
and specific biomarkers such as cTn or the MB fraction of
creatine kinase (CKMB) are increased.2 Cardiac troponin I
and T are components of the contractile apparatus of myo-
cardial cells and are expressed almost exclusively in the heart.
Although elevations of these biomarkers in the blood reflect
injury leading to necrosis of myocardial cells, they do not
indicate the underlying mechanism.5 Various possibilities
have been suggested for release of structural proteins from
the myocardium, including normal turnover of myocardial
cells, apoptosis, cellular release of troponin degradation
products, increased cellular wall permeability, formation and
release of membranous blebs, and myocyte necrosis.6 Re-
gardless of the pathobiology, myocardial necrosis due to
myocardial ischaemia is designated as MI.
Also, histological evidence of myocardial injury with
necrosis may be detectable in clinical conditions associated
with predominantly non-ischaemic myocardial injury. Small
amounts of myocardial injury with necrosis may be detected,
which are associated with heart failure (HF), renal failure,
myocarditis, arrhythmias, pulmonary embolism or otherwise
uneventful percutaneous or surgical coronary procedures.
These should not be labelled as MI or a complication of the
procedures, but rather as myocardial injury, as illustrated in
Figure 1. It is recognized that the complexity of clinical
circumstances may sometimes render it difficult to determine
where individual cases may lie within the ovals of Figure 1.
In this setting, it is important to distinguish acute causes of
cTn elevation, which require a rise and/or fall of cTn values,
from chronic elevations that tend not to change acutely. A list
of such clinical circumstances associated with elevated values
of cTn is presented in Table 1. The multifactorial contribu-
tions resulting in the myocardial injury should be described in
the patient record.
The preferred biomarker—overall and for each specific
category of MI—is cTn (I or T), which has high myocardial
tissue specificity as well as high clinical sensitivity. Detection
of a rise and/or fall of the measurements is essential to the
diagnosis of acute MI.7 An increased cTn concentration is
defined as a value exceeding the 99th percentile of a normal
reference population [upper reference limit (URL)]. This
discriminatory 99th percentile is designated as the decision
level for the diagnosis of MI and must be determined for each
specific assay with appropriate quality control in each labo-
ratory.8,9 The values for the 99th percentile URL defined
by manufacturers, including those for many of the high-
sensitivity assays in development, can be found in the
package inserts for the assays or in recent publications.10,11,12
Values should be presented as nanograms per litre (ng/L)
or picograms per millilitre (pg/mL) to make whole numbers.
Criteria for the rise of cTn values are assay-dependent but can
be defined from the precision profile of each individual assay,
including high-sensitivity assays.10,11 Optimal precision, as
described by coefficient of variation (CV) at the 99th percen-
tile URL for each assay, should be defined as 10%. Better
precision (CV 10%) allows for more sensitive assays and
facilitates the detection of changing values.13 The use of
assays that do not have optimal precision (CV 10% at the
99th percentile URL) makes determination of a significant
change more difficult but does not cause false positive results.
Assays with CV20% at the 99th percentile URL should not
be used.13 It is acknowledged that pre-analytic and analytic
problems can induce elevated and reduced values of cTn.10,11
Blood samples for the measurement of cTn should be
drawn on first assessment and repeated 3–6 h later. Later
samples are required if further ischaemic episodes occur, or
when the timing of the initial symptoms is unclear.14 To
establish the diagnosis of MI, a rise and/or fall in values with
at least one value above the decision level is required,
coupled with a strong pre-test likelihood. The demonstration
of a rising and/or falling pattern is needed to distinguish
Figure 1. This illustration shows various clinical entities: for
example, renal failure, heart failure, tachy- or bradyarrhythmia,
cardiac or non-cardiac procedures that can be associated with
myocardial injury with cell death marked by cardiac troponin
elevation. However, these entities can also be associated with
myocardial infarction in case of clinical evidence of acute myo-
cardial ischaemia with rise and/or fall of cardiac troponin.
Thygesen et al ESC/ACCF/AHA/WHF Third Universal Definition of MI 2023
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acute-from chronic elevations in cTn concentrations that are
associated with structural heart disease.10,11,15–19 For example,
patients with renal failure or HF can have significant chronic
elevations in cTn. These elevations can be marked, as seen in
many patients with MI, but do not change acutely.7 However,
a rising or falling pattern is not absolutely necessary to make
the diagnosis of MI if a patient with a high pre-test risk of MI
presents late after symptom onset; for example, near the peak
of the cTn time-concentration curve or on the slow-declining
portion of that curve, when detecting a changing pattern can
be problematic. Values may remain elevated for 2 weeks or
more following the onset of myocyte necrosis.10
Sex-dependent values may be recommended for high-
sensitivity troponin assays.20,21 An elevated cTn value
(99th percentile URL), with or without a dynamic pattern of
values or in the absence of clinical evidence of ischaemia,
should prompt a search for other diagnoses associated with
myocardial injury, such as myocarditis, aortic dissection,
pulmonary embolism, or HF. Renal failure and other more
non-ischaemic chronic disease states, that can be associated
with elevated cTn levels, are listed in Table 1.10,11
If a cTn assay is not available, the best alternative is
CKMB (measured by mass assay). As with troponin, an
increased CKMB value is defined as a measurement above
the 99th percentile URL, which is designated as the decision
level for the diagnosis of MI.22 Sex-specific values should be
employed.22
Clinical Features of Myocardial Ischaemia
and Infarction
Onset of myocardial ischaemia is the initial step in the
development of MI and results from an imbalance between
oxygen supply and demand. Myocardial ischaemia in a
clinical setting can usually be identified from the patient’s
history and from the ECG. Possible ischaemic symptoms
include various combinations of chest, upper extremity,
mandibular or epigastric discomfort (with exertion or at rest)
or an ischaemic equivalent such as dyspnoea or fatigue. The
discomfort associated with acute MI usually lasts 20 min.
Often, the discomfort is diffuse—not localized, nor posi-
tional, nor affected by movement of the region—and it may
be accompanied by diaphoresis, nausea or syncope. However,
these symptoms are not specific for myocardial ischaemia.
Accordingly, they may be misdiagnosed and attributed to
gastrointestinal, neurological, pulmonary or musculoskeletal
disorders. MI may occur with atypical symptoms—such as
palpitations or cardiac arrest—or even without symptoms; for
example in women, the elderly, diabetics, or post-operative
and critically ill patients.2 Careful evaluation of these patients
is advised, especially when there is a rising and/or falling
pattern of cardiac biomarkers.
Clinical Classification of
Myocardial Infarction
For the sake of immediate treatment strategies, such as
reperfusion therapy, it is usual practice to designate MI in
patients with chest discomfort, or other ischaemic symptoms
that develop ST elevation in two contiguous leads (see ECG
section), as an ‘ST elevation MI’ (STEMI). In contrast,
patients without ST elevation at presentation are usually
designated as having a ‘non-ST elevation MI’ (NSTEMI).
Many patients with MI develop Q waves (Q wave MI), but
others do not (non-Q MI). Patients without elevated bio-
marker values can be diagnosed as having unstable angina. In
addition to these categories, MI is classified into various
types, based on pathological, clinical and prognostic differ-
ences, along with different treatment strategies (Table 2).
Spontaneous Myocardial Infarction (MI Type 1)
This is an event related to atherosclerotic plaque rupture,
ulceration, fissuring, erosion, or dissection with resulting
intraluminal thrombus in one or more of the coronary arteries,
leading to decreased myocardial blood flow or distal platelet
emboli with ensuing myocyte necrosis. The patient may have
underlying severe CAD but, on occasion (5 to 20%), non-
obstructive or no CAD may be found at angiography, partic-
ularly in women.23–25
Myocardial Infarction Secondary to an Ischaemic
Imbalance (MI Type 2)
In instances of myocardial injury with necrosis, where a
condition other than CAD contributes to an imbalance be-
Table 1. Elevations of Cardiac Troponin Values Because of
Myocardial Injury
2024 Circulation October 16, 2012
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tween myocardial oxygen supply and/or demand, the term
‘MI type 2’ is employed (Figure 2). In critically ill patients,
or in patients undergoing major (non-cardiac) surgery, ele-
vated values of cardiac biomarkers may appear, due to the direct
toxic effects of endogenous or exogenous high circulating
catecholamine levels. Also coronary vasospasm and/or endothe-
lial dysfunction have the potential to cause MI.26–28
Cardiac Death Due to Myocardial Infarction (MI
Type 3)
Patients who suffer cardiac death, with symptoms suggestive
of myocardial ischaemia accompanied by presumed new
ischaemic ECG changes or new LBBB—but without avail-
able biomarker values—represent a challenging diagnostic
group. These individuals may die before blood samples for
Table 2. Universal Classification of Myocardial Infarction
Figure 2. Differentiation between myo-
cardial infarction (MI) types 1 and 2
according to the condition of the coro-
nary arteries.
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biomarkers can be obtained, or before elevated cardiac
biomarkers can be identified. If patients present with clinical
features of myocardial ischaemia, or with presumed newisch-
aemic ECG changes, they should be classified as having had a
fatal MI, even if cardiac biomarker evidence of MI is lacking.
Myocardial Infarction Associated With
Revascularization Procedures (MI Types 4 and 5)
Periprocedural myocardial injury or infarction may occur at
some stages in the instrumentation of the heart that is required
during mechanical revascularization procedures, either by
PCI or by coronary artery bypass grafting (CABG). Elevated
cTn values may be detected following these procedures, since
various insults may occur that can lead to myocardial injury
with necrosis.29–32 It is likely that limitation of such injury is
beneficial to the patient: however, a threshold for a worsening
prognosis, related to an asymptomatic increase of cardiac
biomarker values in the absence of procedural complications,
is not well defined.33–35 Subcategories of PCI-related MI are
connected to stent thrombosis and restenosis that may happen
after the primary procedure.
Electrocardiographic Detection of
Myocardial Infarction
The ECG is an integral part of the diagnostic work-up of patients
with suspected MI and should be acquired and interpreted
promptly (i.e. target within 10 min) after clinical presentation.2
Dynamic changes in the ECG waveforms during acute myocar-
dial ischaemic episodes often require acquisition of multiple
ECGs, particularly if the ECG at initial presentation is non-di-
agnostic. Serial recordings in symptomatic patients with an
initial non-diagnostic ECG should be performed at 15–30 min
intervals or, if available, continuous computer-assisted 12-lead
ECG recording. Recurrence of symptoms after an asymptomatic
interval are an indication for a repeat tracing and, in patients with
evolving ECG abnormalities, a pre-discharge ECG should be
acquired as a baseline for future comparison. Acute or evolving
changes in the ST-T waveforms and Q waves, when present,
potentially allow the clinician to time the event, to identify the
infarct-related artery, to estimate the amount of myocardium at
risk as well as prognosis, and to determine therapeutic strategy.
More profound ST-segment shift or T wave inversion involving
multiple leads/territories is associated with a greater degree of
myocardial ischaemia and a worse prognosis. Other ECG signs
associated with acute myocardial ischaemia include cardiac
arrhythmias, intraventricular and atrioventricular conduction de-
lays, and loss of pre-cordial R wave amplitude. Coronary artery
size and distribution of arterial segments, collateral vessels,
location, extent and severity of coronary stenosis, and prior
myocardial necrosis can all impact ECG manifestations of
myocardial ischae-mia.36 Therefore the ECG at presentation
should always be compared to prior ECG tracings, when
available. The ECG by itself is often insufficient to diagnose
acute myocardial ischaemia or infarction, since ST deviation
may be observed in other conditions, such as acute pericarditis,
left ventricular hypertrophy (LVH), left bundle branch block
(LBBB), Brugada syndrome, stress cardiomyopathy, and early
repolarization patterns.37 Prolonged new ST-segment elevation
(e.g. 20 min), particularly when associated with reciprocal
ST-segment depression, usually reflects acute coronary occlu-
sion and results in myocardial injury with necrosis. As in
cardiomyopathy, Q waves may also occur due to myocardial
fibrosis in the absence of CAD.
ECG abnormalities of myocardial ischaemia or infarction
may be inscribed in the PR segment, the QRS complex, the
ST-segment or the T wave. The earliest manifestations of
myocardial ischaemia are typically T wave and ST-segment
changes. Increased hyperacute T wave amplitude, with promi-
nent symmetrical T waves in at least two contiguous leads, is an
early sign that may precede the elevation of the ST-segment.
Transient Q waves may be observed during an episode of acute
ischaemia or (rarely) during acute MI with successful reperfu-
sion. Table 3 lists ST-T wave criteria for the diagnosis of acute
myocardial ischaemia that may or may not lead to MI. The J
point is used to determine the magnitude of the ST-segment
shift. New, or presumed new, J point elevation 0.1 mV is
required in all leads other than V2 and V3. In healthy men under
age 40, J-point elevation can be as much as 0.25 mV in leads V2
or V3, but it decreases with increasing age. Sex differences
require different cut-points for women, since J point elevation in
healthy women in leads V2 and V3 is less than in men.38
‘Contiguous leads’ refers to lead groups such as anterior leads
(V1–V6), inferior leads (II, III, aVF) or lateral/apical leads (I,
aVL). Supplemental leads such as V3R and V4R reflect the free
wall of the right ventricle and V7–V9 the infero-basal wall.
The criteria in Table 3 require that the ST shift be present in
two or more contiguous leads. For example, 0.2 mV of ST
elevation in lead V2, and 0.1 mV in lead V1, would meet the
criteria of two abnormal contiguous leads in a man 40 years
old. However, 0.1 mV and 0.2 mV of ST elevation, seen
only in leads V2–V3 in men (or 0.15 mV in women), may
represent a normal finding. It should be noted that, occasionally,
acute myocardial ischaemia may create sufficient ST-segment
shift to meet the criteria in one lead but have slightly less than the
required ST shift in a contiguous lead. Lesser degrees of ST
displacement or T wave inversion do not exclude acute myocar-
dial ischaemia or evolving MI, since a single static recording
may miss the more dynamic ECG changes that might be
detected with serial recordings. ST elevation or diagnostic Q
waves in contiguous lead groups are more specific than ST
depression in localizing the site of myocardial ischaemia or
necrosis.39,40 Supplemental leads, as well as serial ECG record-
ings, should always be considered in patients that present with
Table 3. ECG Manifestations of Acute Myocardial Ischaemia
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ischaemic chest pain and a non-diagnostic initial ECG.41,42
Electrocardiographic evidence of myocardial ischaemia in the
distribution of a left circumflex artery is often overlooked and is
best captured using posterior leads at the fifth intercostal space
(V7 at the left posterior axillary line, V8 at the left mid-scapular
line, and V9 at the left paraspinal border). Recording of these
leads is strongly recommended in patients with high clinical
suspicion for acute circumflex occlusion (for example, initial
ECG non-diagnostic, or ST-segment depression in leads V1–3).41
A cut-point of 0.05 mV ST elevation is recommended in leads
V7–V9; specificity is increased at a cut-point 0.1 mV ST
elevation and this cut-point should be used in men 40 years
old. ST depression in leads V1–V3 may be suggestive of
infero-basal myocardial ischaemia (posterior infarction), espe-
cially when the terminal T wave is positive (ST elevation
equivalent), however this is non-specific.41–43 In patients with
inferior and suspected right ventricular infarction, right pre-
cordial leads V3R and V4R should be recorded, since ST
elevation0.05 mV (0.1 mV in men30 years old) provides
supportive criteria for the diagnosis.42
During an episode of acute chest discomfort, pseudo-
normalization of previously inverted T waves may indicate
acute myocardial ischaemia. Pulmonary embolism, intracra-
nial processes, electrolyte abnormalities, hypothermia, or
peri-/myocarditis may also result in ST-T abnormalities
and should be considered in the differential diagnosis. The
diagnosis of MI is more difficult in the presence of LBBB.44,45
However, concordant ST-segment elevation or a previous ECG
may be helpful to determine the presence of acute MI in this
setting. In patients with right bundle branch block (RBBB),
ST-T abnormalities in leads V1–V3 are common, making it
difficult to assess the presence of ischaemia in these leads:
however, when new ST elevation or Q waves are found,
myocardial ischaemia or infarction should be considered.
Prior Myocardial Infarction
As shown in Table 4, Q waves or QS complexes in the absence
of QRS confounders are pathognomonic of a prior MI in patients
with ischaemic heart disease, regardless of symptoms.46,47 The
specificity of the ECG diagnosis for MI is greatest when Q
waves occur in several leads or lead groupings. When the Q
waves are associated with ST deviations or T wave changes in
the same leads, the likelihood of MI is increased; for example,
minor Q waves0.02 sec and0.03 sec that are0.1 mV deep
are suggestive of prior MI if accompanied by inverted T waves
in the same lead group. Other validated MI coding algorithms,
such as the Minnesota Code and WHO MONICA, have been
used in epidemiological studies and clinical trials.3
Silent Myocardial Infarction
Asymptomatic patients who develop new pathologic Q wave
criteria for MI detected during routine ECG follow-up, or
reveal evidence of MI by cardiac imaging, that cannot be
directly attributed to a coronary revascularization procedure,
should be termed ‘si lent MI.’48–51 In studies, silent Q wave
MI accounted for 9–37% of all non-fatal MI events and were
associated with a significantly increased mortality risk.48,49
Improper lead placement or QRS confounders may result in
what appear to be new Q waves or QS complexes, as compared
to a prior tracing. Thus, the diagnosis of a new silent Q wave MI
should be confirmed by a repeat ECG with correct lead place-
ment, or by an imaging study, and by focussed questioning about
potential interim ischaemic symptoms.
Conditions That Confound the ECG Diagnosis
of Myocardial Infarction
A QS complex in lead V1 is normal. A Q wave 0.03 sec and
25% of the R wave amplitude in lead III is normal if the frontal
QRS axis is between 30° and 0°. A Q wave may also be
normal in aVL if the frontal QRS axis is between 60° and 90°.
Septal Q waves are small, non-pathological Q waves0.03 sec
and 25% of the R-wave amplitude in leads I, aVL, aVF, and
V4–V6. Pre-excitation, obstructive, dilated or stress cardiomy-
opathy, cardiac amyloidosis, LBBB, left anterior hemiblock,
LVH, right ventricular hypertrophy, myocarditis, acute cor
pulmonale, or hyperkalaemia may be associated with Q waves
or QS complexes in the absence of MI. ECG abnormalities that
mimic myocardial ischaemia or MI are presented in Table 5.
Imaging Techniques
Non-invasive imaging plays many roles in patients with
known or suspected MI, but this section concerns only its role
Table 4. ECG Changes Associated With Prior Myocardial
Infarction (in Absence of LVH and LBBB)
aThe same criteria are used for supplemental leads V7–V9.
Table 5. Common ECG Pitfalls in Diagnosing Myocardial
Infarction
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in the diagnosis and characterisation of MI. The underlying
rationale is that regional myocardial hypoperfusion and isch-
aemia lead to a cascade of events, including myocardial
dysfunction, cell death and healing by fibrosis. Important
imaging parameters are therefore perfusion, myocyte viabil-
ity, myocardial thickness, thickening and motion, and the
effects of fibrosis on the kinetics of paramagnetic or radio-
opaque contrast agents.
Commonly used imaging techniques in acute and chronic
infarction are echocardiography, radionuclide ventriculogra-
phy, myocardial perfusion scintigraphy (MPS) using single
photon emission computed tomography (SPECT), and mag-
netic resonance imaging (MRI). Positron emission tomogra-
phy (PET) and X-ray computed tomography (CT) are less
common.52 There is considerable overlap in their capabilities
and each of the techniques can, to a greater or lesser extent,
assess myocardial viability, perfusion, and function. Only the
radionuclide techniques provide a direct assessment of myo-
cyte viability, because of the inherent properties of the tracers
used. Other techniques provide indirect assessments of myo-
cardial viability, such as contractile response to dobutamine
by echocardiography or myocardial fibrosis by MR.
Echocardiography
The strength of echocardiography is the assessment of cardiac
structure and function, in particular myocardial thickness,
thickening and motion. Echocardiographic contrast agents
can improve visualisation of the endocardial border and can
be used to assess myocardial perfusion and microvascular
obstruction. Tissue Doppler and strain imaging permit quan-
tification of global and regional function.53 Intravascular
echocardiographic contrast agents have been developed that
target specific molecular processes, but these techniques have
not yet been applied in the setting of MI.54
Radionuclide Imaging
Several radionuclide tracers allow viable myocytes to be
imaged directly, including the SPECT tracers thallium-201,
technetium-99m MIBI and tetrofosmin, and the PET tracers
F-2-fluorodeoxyglucose (FDG) and rubidium-82.18,52 The
strength of the SPECT techniques is that these are the only
commonly available direct methods of assessing viability,
although the relatively low resolution of the images leaves
them at a disadvantage for detecting small areas of MI. The
common SPECT radiopharmaceuticals are also tracers of
myocardial perfusion and the techniques thereby readily
detect areas of MI and inducible perfusion abnormalities.
ECG-gated imaging provides a reliable assessment of myo-
cardial motion, thickening and global function. Evolving
radionuclide techniques that are relevant to the assessment
of MI include imaging of sympathetic innervation using
iodine-123-labelled meta-iodo-benzylguanidine (mIBG),55
imaging of matrix metalloproteinase activation in ventric-
ular remodelling,56,57 and refined assessment of myocar-
dial metabolism.58
Magnetic Resonance Imaging
The high tissue contrast of cardiovascular MRI provides an
accurate assessment of myocardial function and it has similar
capability to echocardiography in suspected acute MI. Para-
magnetic contrast agents can be used to assess myocardial
perfusion and the increase in extracellular space that is
associated with the fibrosis of prior MI. These techniques
have been used in the setting of acute MI,59,60 and imaging of
myocardial fibrosis by delayed contrast enhancement is able
to detect even small areas of subendocardial MI. It is also of
value in detecting myocardial disease states that can mimic
MI, such as myocarditis.61
Computed Tomography
Infarcted myocardium is initially visible as a focal area of
decreased left ventricle (LV) enhancement, but later imaging
shows hyper- enhancement, as with late gadolinium imaging
by MRI.62 This finding is clinically relevant because contrast-
enhanced CT may be performed for suspected pulmonary
embolism and aortic dissection—conditions with clinical
features that overlap with those of acute MI—but the tech-
nique is not used routinely. Similarly, CT assessment of
myocardial perfusion is technically feasible but not yet fully
validated.
Applying Imaging in Acute Myocardial Infarction
Imaging techniques can be useful in the diagnosis of acute MI
because of their ability to detect wall motion abnormalities or
loss of viable myocardium in the presence of elevated cardiac
biomarker values. If, for some reason, biomarkers have not
been measured or may have normalized, demonstration of
new loss of myocardial viability in the absence of non-
ischaemic causes meets the criteria for MI. Normal function
and viability have a very high negative predictive value and
practically exclude acute MI.63 Thus, imaging techniques are
useful for early triage and discharge of patients with sus-
pected MI. However, if biomarkers have been measured at
appropriate times and are normal, this excludes an acute MI
and takes precedence over the imaging criteria.
Abnormal regional myocardial motion and thickening may
be caused by acute MI or by one or more of several other
conditions, including prior MI, acute ischaemia, stunning or
hibernation. Non-ischaemic conditions, such as cardiomyop-
athy and inflammatory or infiltrative diseases, can also lead to
regional loss of viable myocardium or functional abnormal-
ity. Therefore, the positive predictive value of imaging for
acute MI is not high unless these conditions can be excluded,
and unless a new abnormality is detected or can be presumed
to have arisen in the setting of other features of acute MI.
Echocardiography provides an assessment of many non-
ischaemic causes of acute chest pain, such as peri-myocarditis,
valvular heart disease, cardiomyopathy, pulmonary embo-
lism or aortic dissection.53 It is the imaging technique of
choice for detecting complications of acute MI, including
myocardial free wall rupture, acute ventricular septal
defect, and mitral regurgitation secondary to papillary
muscle rupture or ischaemia.
Radionuclide imaging can be used to assess the amount of
myocardium that is salvaged by acute revascularization.64
Tracer is injected at the time of presentation, with imaging
deferred until after revascularization, providing a measure of
myocardium at risk. Before discharge, a second resting
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injection provides a measure of final infarct size, and the
difference between the two corresponds to the myocardium
that has been salvaged.
Applying Imaging in Late Presentation of
Myocardial Infarction
In case of late presentation after suspected MI, the presence
of regional wall motion abnormality, thinning or scar in the
absence of non- ischaemic causes, provides evidence of past
MI. The high resolution and specificity of late gadolinium
enhancement MRI for the detection of myocardial fibrosis
has made this a very valuable technique. In particular, the
ability to distinguish between subendocardial and other pat-
terns of fibrosis provides a differentiation between ischaemic
heart disease and other myocardial abnormalities. Imaging
techniques are also useful for risk stratification after a
definitive diagnosis of MI. The detection of residual or
remote ischaemia and/or ventricular dysfunction provides
powerful indicators of later outcome.
Diagnostic Criteria for Myocardial Infarction
With PCI (MI Type 4)
Balloon inflation during PCI often causes transient ischaemia,
whether or not it is accompanied by chest pain or ST-T
changes. Myocardial injury with necrosis may result from
recognizable peri-procedural events—alone or in combina-
tion—such as coronary dissection, occlusion of a major
coronary artery or a side-branch, disruption of collateral flow,
slow flow or no-reflow, distal embolization, and microvas-
cular plugging. Embolization of intracoronary thrombus or
atherosclerotic particulate debris may not be preventable,
despite current anticoagulant and antiplatelet adjunctive ther-
apy, aspiration or protection devices. Such events induce
inflammation of the myocardium surrounding islets of myo-
cardial necrosis.65 New areas of myocardial necrosis have
been demonstrated by MRI following PCI.66
The occurrence of procedure-related myocardial cell injury
with necrosis can be detected by measurement of cardiac
biomarkers before the procedure, repeated 3–6 h later and,
optionally, further re-measurement 12 h thereafter. Increasing
levels can only be interpreted as procedure-related myocardial
injury if the pre-procedural cTn value is normal (99th percen-
tile URL) or if levels are stable or falling.67,68 In patients with
normal pre-procedural values, elevation of cardiac biomarker
values above the 99th percentile URL following PCI are indic-
ative of procedure-related myocardial injury. In earlier studies,
increased values of post-procedural cardiac biomarkers, espe-
cially CKMB, were associated with impaired outcome.69,70
However, when cTn concentrations are normal before PCI and
become abnormal after the procedure, the threshold above the
99th percentile URL—whereby an adverse prognosis is evi-
dent—is not well defined71 and it is debatable whether such a
threshold even exists.72 If a single baseline cTn value is elevated,
it is impossible to determine whether further increases are due to
the procedure or to the initial process causing the elevation. In
this situation, it appears that the prognosis is largely determined
by the pre-procedural cTn level.71 These relationships will
probably become even more complex for the new high-
sensitivity troponin assays.70
In patients undergoing PCI with normal (99th percentile
URL) baseline cTn concentrations, elevations of cTn 5
99th percentile URL occurring within 48 h of the procedure—
plus either (i) evidence of prolonged ischaemia (20 min) as
demonstrated by prolonged chest pain, or (ii) ischaemic ST
changes or new pathological Q waves, or (iii) angiographic
evidence of a flow limiting complication, such as of loss of
patency of a side branch, persistent slow-flow or no-reflow,
embolization, or (iv) imaging evidence of new loss of viable
myocardium or new regional wall motion abnormality—is
defined as PCI-related MI (type 4a). This threshold of cTn
values 599th percentile URL is arbitrarily chosen, based on
clinical judgement and societal implications of the label of
peri-procedural MI. When a cTn value is 599th percentile
URL after PCI and the cTn value was normal before the
PCI—or when the cTn value is599th percentile URL in the
absence of ischaemic, angiographic or imaging findings—the
term ‘myocardial injury’ should be used.
If the baseline cTn values are elevated and are stable or
falling, then a rise of 20% is required for the diagnosis of a
type 4a MI, as with reinfarction. Recent data suggest that,
when PCI is delayed after MI until biomarker concentrations
are falling or have normalized, and elevation of cardiac
biomarker values then reoccurs, this may have some long-
term significance. However, additional data are needed to
confirm this finding.73
A subcategory of PCI-related MI is stent thrombosis, as
documented by angiography and/or at autopsy and a rise
and/or fall of cTn values 99th percentile URL (identified as
MI type 4b). In order to stratify the occurrence of stent
thrombosis in relation to the timing of the PCI procedure, the
Academic Research Consortium recommends temporal cate-
gories of ‘early’ (0 to 30 days), ‘late’ (31 days to 1 year), and
‘very late’ (1 year) to distinguish likely differences in the
contribution of the various pathophysiological processes dur-
ing each of these intervals.74 Occasionally, MI occurs in the
clinical setting of what appears to be a stent thrombosis:
however, at angiography, restenosis is observed without
evidence of thrombus (see section on clinical trials).
Diagnostic Criteria for Myocardial Infarction
With CABG (MI Type 5)
During CABG, numerous factors can lead to periprocedural
myocardial injury with necrosis. These include direct myo-
cardial trauma from (i) suture placement or manipulation of
the heart, (ii) coronary dissection, (iii) global or regional
ischaemia related to inadequate intra-operative cardiac pro-
tection, (iv) microvascular events related to reperfusion, (v)
myocardial injury induced by oxygen free radical generation,
or (vi) failure to reperfuse areas of the myocardium that are
not subtended by graftable vessels.75–77 MRI studies suggest
that most necrosis in this setting is not focal but diffuse and
localized in the subendocardium.78
In patients with normal values before surgery, any increase
of cardiac biomarker values after CABG indicates myocardial
necrosis, implying that an increasing magnitude of biomarker
concentrations is likely to be related to an impaired outcome.
This has been demonstrated in clinical studies employing
CKMB, where elevations 5, 10 and 20 times the URL after
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CABG were associated with worsened prognosis; similarly,
impaired outcome has been reported when cTn values were
elevated to the highest quartile or quintile of the
measurements.79–83
Unlike prognosis, scant literature exists concerning the use
of biomarkers for defining an MI related to a primary vascular
event in a graft or native vessel in the setting of CABG. In
addition, when the baseline cTn value is elevated (99th
percentile URL), higher levels of biomarker values are seen
post-CABG. Therefore, biomarkers cannot stand alone in
diagnosing MI in this setting. In view of the adverse impact
on survival observed in patients with significant elevation of
biomarker concentrations, this Task Force suggests, by arbi-
trary convention, that cTn values 1099th percentile URL
during the first 48 h following CABG, occurring from a
normal baseline cTn value (99th percentile URL). In
addition, either (i) new pathological Q waves or new LBBB,
or (ii) angiographically documented new graft or new native
coronary artery occlusion, or (iii) imaging evidence of new
loss of viable myocardium or new regional wall motion
abnormality, should be considered as diagnostic of a CABG-
related MI (type 5). Cardiac biomarker release is considerably
higher after valve replacement with CABG than with bypass
surgery alone, and with on-pump CABG compared to off-
pump CABG.84 The threshold described above is more robust
for isolated on-pump CABG. As for PCI, the existing
principles from the universal definition of MI should be
applied for the definition of MI 48 h after surgery.
Assessment of MI in Patients Undergoing
Other Cardiac Procedures
New ST-T abnormalities are common in patients who un-
dergo cardiac surgery. When new pathological Q waves
appear in different territories than those identified before
surgery, MI (types 1 or 2) should be considered, particularly
if associated with elevated cardiac biomarker values, new
wall motion abnormalities or haemodynamic instability.
Novel procedures such as transcatheter aortic valve im-
plantation (TAVI) or mitral clip may cause myocardial injury
with necrosis, both by direct trauma to the myocardium and
by creating regional ischaemia from coronary obstruction or
embolization. It is likely that, similarly to CABG, the more
marked the elevation of the biomarker values, the worse the
prognosis—but data on that are not available.
Modified criteria have been proposed for the diagnosis of
periprocedural MI 72 h after aortic valve implantation.85
However, given that there is too little evidence, it appears
reasonable to apply the same criteria for procedure-related MI
as stated above for CABG.
Ablation of arrhythmias involves controlled myocardial
injury with necrosis, by application of warming or cooling of
the tissue. The extent of the injury with necrosis can be
assessed by cTn measurement: however, an elevation of cTn
values in this context should not be labelled as MI.
Myocardial Infarction Associated With
Non-Cardiac Procedures
Perioperative MI is the most common major perioperative
vascular complication in major non-cardiac surgery, and is
associated with a poor prognosis.86,87 Most patients who have
a perioperative MI will not experience ischaemic symptoms.
Nevertheless, asymptomatic perioperative MI is as strongly
associated with 30-day mortality, as is symptomatic MI.86
Routine monitoring of cardiac biomarkers in high-risk pa-
tients, both prior to and 48–72 h after major surgery, is
therefore recommended. Measurement of high-sensitivity
cTn in post-operative samples reveals that 45% of patients
have levels above the 99th percentile URL and 22% have an
elevation and a rising pattern of values indicative of evolving
myocardial necrosis.88 Studies of patients undergoing major
non-cardiac surgery strongly support the idea that many of
the infarctions diagnosed in this context are caused by a
prolonged imbalance between myocardial oxygen supply and
demand, against a background of CAD.89,90 Together with a
rise and/or fall of cTn values, this indicates MI type 2.
However, one pathological study of fatal perioperative MI
patients showed plaque rupture and platelet aggregation,
leading to thrombus formation, in approximately half of such
events;91 that is to say, MI type 1. Given the differences that
probably exist in the therapeutic approaches to each, close
clinical scrutiny and judgement is needed.
Myocardial Infarction in the Intensive
Care Unit
Elevations of cTn values are common in patients in the intensive
care unit and are associated with adverse prognosis, regardless of
the underlying disease state.92,93 Some elevations may reflect MI
type 2 due to underlying CAD and increased myocardial oxygen
demand.94 Other patients may have elevated values of cardiac
biomarkers, due to myocardial injury with necrosis induced by
catecholamine or direct toxic effect from circulating toxins.
Moreover, in some patients, MI type 1 may occur. It is often a
challenge for the clinician, caring for a critically ill patient with
severe single organ or multi-organ pathology, to decide on a plan
of action when the patient has elevated cTn values. If and when
the patient recovers from the critical illness, clinical judgement
should be employed to decide whether—and to what extent—
further evaluation for CAD or structural heart disease is
indicated.95
Recurrent Myocardial Infarction
‘Incident MI’ is defined as the individual’s first MI. When
features of MI occur in the first 28 days after an incident
event, this is not counted as a new event for epidemiological
purposes. If characteristics of MI occur after 28 days follow-
ing an incident MI, it is considered to be a recurrent MI.3
Reinfarction
The term ‘reinfarction’ is used for an acute MI that occurs within
28 days of an incident- or recurrent MI.3 The ECG diagnosis of
suspected reinfarction following the initial MI may be con-
founded by the initial evolutionary ECG changes. Reinfarction
should be considered when ST elevation 0.1 mV recurs, or
new pathognomonic Q waves appear, in at least two contiguous
leads, particularly when associated with ischaemic symptoms for
20 min or longer. Re-elevation of the ST-segment can, however,
also be seen in threatened myocardial rupture and should lead to
additional diagnostic workup. ST depression or LBBB alone are
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non-specific findings and should not be used to diagnose
reinfarction.
In patients in whom reinfarction is suspected from clinical
signs or symptoms following the initial MI, an immediate
measurement of cTn is recommended. A second sample should
be obtained 3–6 h later. If the cTn concentration is elevated, but
stable or decreasing at the time of suspected reinfarction, the
diagnosis of reinfarction requires a 20% or greater increase of
the cTn value in the second sample. If the initial cTn concen-
tration is normal, the criteria for new acute MI apply.
Myocardial Injury or Infarction Associated
With Heart Failure
Depending on the assay used, detectable-to-clearly elevated
cTn values, indicative of myocardial injury with necrosis,
may be seen in patients with HF syndrome.96 Using high-
sensitivity cTn assays, measurable cTn concentrations may be
present in nearly all patients with HF, with a significant
percentage exceeding the 99th percentile URL, particularly in
those with more severe HF syndrome, such as in acutely
decompensated HF.97
Whilst MI type 1 is an important cause of acutely decom-
pensated HF—and should always be considered in the con-
text of an acute presentation—elevated cTn values alone, in
a patient with HF syndrome, do not establish the diagnosis of
MI type 1 and may, indeed, be seen in those with non-
ischaemic HF. Beyond MI type 1, multiple mechanisms have
been invoked to explain measurable-to-pathologically ele-
vated cTn concentrations in patients with HF.96,97 For exam-
ple, MI type 2 may result from increased transmural pressure,
small-vessel coronary obstruction, endothelial dysfunction,
anaemia or hypotension. Besides MI type 1 or 2, cardiomyo-
cyte apoptosis and autophagy due to wall stretch has been
experimentally demonstrated. Direct cellular toxicity related
to inflammation, circulating neurohormones, infiltrative pro-
cesses, as well as myocarditis and stress cardiomyopathy,
may present with HF and abnormal cTn measurement.97
Whilst prevalent and complicating the diagnosis of MI, the
presence, magnitude and persistence of cTn elevation in HF is
increasingly accepted to be an independent predictor of adverse
outcomes in both acute and chronic HF syndrome, irrespective
of mechanism, and should not be discarded as ‘false
positive.’97,98
In the context of an acutely decompensated HF presentation,
cTn I or T should always be promptly measured and ECG
recorded, with the goal of identifying or excluding MI type 1 as
the precipitant. In this setting, elevated cTn values should be
interpreted with a high level of suspicion for MI type 1 if a
significant rise and/or fall of the marker are seen, or if it is
accompanied by ischaemic symptoms, new ischaemic ECG
changes or loss of myocardial function on non-invasive testing.
Coronary artery anatomy may often be well-known; such
knowledge may be used to interpret abnormal troponin results. If
normal coronary arteries are present, either a type 2 MI or a
non-coronary mechanism for troponin release may be invoked.97
On the other hand, when coronary anatomy is not estab-
lished, the recognition of a cTn value in excess of the 99th
percentile URL alone is not sufficient to make a diagnosis of
acute MI due to CAD, nor is it able to identify the mechanism
for the abnormal cTn value. In this setting, further informa-
tion, such as myocardial perfusion studies, coronary angiog-
raphy, or MRI is often required to better understand the cause
of the abnormal cTn measurement. However, it may be
difficult to establish the reason for cTn abnormalities, even
after such investigations.96,97
Application of MI in Clinical Trials and
Quality Assurance Programmes
In clinical trials, MI may be an entry criterion or an end-point. A
universal definition for MI is of great benefit for clinical studies,
since it will allow a standardized approach for interpretation and
comparison across different trials. The definition of MI as an
entry criterion, e.g. MI type 1 and not MI type 2, will determine
patient characteristics in the trial. Occasionally MI occurs and, at
angiography, restenosis is the only angiographic explana-
tion.99,100 This PCI-related MI type might be designated as an
‘MI type 4c,’ defined as50% stenosis at coronary angiography
or a complex lesion associated with a rise and/or fall of cTn
values 99th percentile URL and no other significant obstruc-
tive CAD of greater severity following: (i) initially successful
stent deployment or (ii) dilatation of a coronary artery stenosis
with balloon angioplasty (50%).
In recent investigations, different MI definitions have been
employed as trial outcomes, thereby hampering comparison
and generalization between these trials. Consistency among
investigators and regulatory authorities, with regard to the
definition of MI used as an endpoint in clinical investigations,
is of substantial value. Adaptation of the definition to an
individual clinical study may be appropriate in some circum-
stances and should have a well-articulated rationale. No
matter what, investigators should ensure that a trial provides
comprehensive data for the various types of MI and includes
the 99th percentile URL decision limits of cTn or other
biomarkers employed. Multiples of the 99th percentiles URL
may be indicated as shown in Table 6. This will facilitate
comparison of trials and meta-analyses.
Because different assays may be used, including newer,
higher-sensitivity cTn assays in large multicentre clinical trials,
it is advisable to consistently apply the 99th percentile URL.
This will not totally harmonize troponin values across different
assays, but will improve the consistency of the results. In
patients undergoing cardiac procedures, the incidence of MI may
be used as a measure of quality, provided that a consistent
definition is applied by all centres participating in the quality
assurance programme. To be effective and to avoid bias, this
type of assessment will need to develop a paradigm to harmo-
nize the different cTn assay results across sites.
Public Policy Implications of the Adjustment
of the MI Definition
Revision of the definition of MI has a number of implications for
individuals as well as for society at large. A tentative or final
diagnosis is the basis for advice about further diagnostic testing,
lifestyle changes, treatment and prognosis for the patient. The
aggregate of patients with a particular diagnosis is the basis for
health care planning and policy and resource allocation.
One of the goals of good clinical practice is to reach a
definitive and specific diagnosis, which is supported by
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current scientific knowledge. The approach to the definition
of MI outlined in this document meets this goal. In general,
the conceptual meaning of the term ‘myocardial infarction’
has not changed, although new, sensitive diagnostic methods
have been developed to diagnose this entity. Thus, the
diagnosis of acute MI is a clinical diagnosis based on patient
symptoms, ECG changes, and highly sensitive biochemical
markers, as well as information gleaned from various imaging
techniques. It is important to characterize the type of MI as
well as the extent of the infarct, residual LV function, and the
severity of CAD and other risk factors, rather than merely
making a diagnosis of MI. The information conveyed about
the patient’s prognosis and ability to work requires more than
just the mere statement that the patient has suffered an MI.
The many additional factors just mentioned are also required
so that appropriate social, family, and employment decisions
can be made. A number of risk scores have been developed to
redict the prognosis after MI. The classification of the various
other prognostic entities associated with MI should lead to a
reconsideration of the clinical coding entities currently employed
for patients with the myriad conditions that can lead to myocar-
dial necrosis, with consequent elevation of biomarker values.
It should be appreciated that the current modification of the
definition of MI may be associated with consequences for the
patients and their families in respect of psychological status,
life insurance, professional career, as well as driving- and
pilots’ licences. The diagnosis is associated also with societal
implications as to diagnosis-related coding, hospital reim-
bursement, public health statistics, sick leave, and disability
attestation. In order to meet this challenge, physicians must be
adequately informed of the altered diagnostic criteria. Educa-
tional materials will need to be created and treatment guidelines
must be appropriately adapted. Professional societies and health-
care planners should take steps to facilitate the rapid dissemina-
tion of the revised definition to physicians, other health care
professionals, administrators, and the general public.
Global Perspectives of the Definition of
Myocardial Infarction
Cardiovascular disease is a global health problem. Under-
standing the burden and effects of CAD in populations is of
critical importance. Changing clinical definitions, criteria and
biomarkers add challenges to our understanding and ability to
improve the health of the public. The definition of MI for
clinicians has important and immediate therapeutic implica-
tions. For epidemiologists, the data are usually retrospective,
so consistent case definitions are critical for comparisons and
trend analysis. The standards described in this report are
suitable for epidemiology studies. However, to analyse trends
over time, it is important to have consistent definitions and to
quantify adjustments when biomarkers or other diagnostic
criteria change.101 For example, the advent of cTn dramati-
cally increased the number of diagnosable MIs for
epidemiologists.3,102
In countries with limited economic resources, cardiac
biomarkers and imaging techniques may not be available
except in a few centres, and even the option of ECG
recordings may be lacking. In these surroundings, the WHO
states that biomarker tests or other high-cost diagnostic
testing are unfit for use as compulsory diagnostic criteria.3
The WHO recommends the use of the ESC/ACCF/AHA/
WHF Universal MI Definition in settings without resource
constraints, but recommends more flexible standards in
resource-constrained locations.3
Cultural, financial, structural and organisational problems in
the different countries of the world in the diagnosis and therapy
of acute MI will require ongoing investigation. It is essential that
the gap between therapeutic and diagnostic advances be ad-
dressed in this expanding area of cardiovascular disease.
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B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Bristol Myers Squibb : Thrombosis (2010)
D - Research funding (departmental or institutional).
                - Institutional : Atherosclerosis (2010)
Hamm Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Daiichi Sankyo : drugs (2010-2011)
                - Pfizer : drugs (2010-2011)
                - Sanofi Aventis : drugs (2010-2011)
                - GlaxoSmithKline : drugs (2010-2011)
                - Menarini : drugs (2010-2011)
                - Berlin Chemie AG : drugs (2010-2011)
                - Heart.org : drugs (2010-2011)
                - Medicines Company : drugs (2010-2011)
                - Boehringer Ingelheim - Ingelheim; Daiichi-Sankyo/Eli Lilly; Nycomed Pharma : drugs (2010-2011)
                - Takeda Pharmaceuticals : drugs (2010-2011)
                - Astra Zeneca, Bayer AG, Boehringer-Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier : drugs 
(2010-2011)
                - Merck Sharp & Dohme : drugs (2010-2011)
                - BRAHMS GmbH : markers (2010-2011)
                - Siemens Healthcare : MRI (2010-2011)
                - Boston Scientific : PCI (2010-2011)
                - Cordis and Medtronic : PCI (2010-2011)
Hod Hanoch
                - Sanofi Aventis : Israeli PI in TAO trial (2010)
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Hu Dayi None
Jaffe Allan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Amgen : biomarkers (2010)
                - Pfizer : biomarkers (2010)
                - Beckman Coulter : biomarkers (2010)
                - Roche Pharma : biomarkers (2010)
                - Alere : biomarkers (2010)
                - Critical Diagnostics : biomarkers (2010)
                - Tethys Bioscience : biomarkers (2010)
                - Critical Diagnostics : ST2 (2011)
                - Amgen : troponin (2011)
                - Beckman Coulter : troponin (2011)
                - Abbott Laboratories : troponin (2011)
                - Alere : troponin (2011)
                - Radiometer : troponin (2011)
                - Roche Diagnostics : troponin (2011)
                - Theheart.org : troponin (2011)
                - OrthoClinical Diagnostics : troponin + other analytes (2011)
E - Research funding (personal).
                - Beckman Coulter : biomarkers (2010)
Januzzi James A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Roche Pharma : biomarkers (2010-2011)
                - Critical Diagnostics : biomarkers (2010-2011)
D - Research funding (departmental or institutional).
                - Siemens Healthcare : Biomarkers (2010)
                - Roche Pharma : biomarkers (2010)
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Januzzi James                 - Critical Diagnostics : Biomarkers (2010)
                - BRAHMS GmbH : Biomarkers (2011)
                - Siemens Healthcare : Biomarkers (2011)
                - Roche Pharma : biomarkers (2011)
Johanson Per A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca : acute coronary care (2010-2011)
                - Medicines Company : acute coronary care (2010)
                - Astra Zeneca : ACS (2011)
                - Lilly : ACS (2011)
Katus Hugo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca; Bayer; Daiichi Sankyo; Roche Diagnostics, Menarini, : Ticagrelor, Rivaroxaban, Prasugrel, Troponin T, 
Ranolazine (2011)
                - Astra Zeneca; Bayer; Daiichi Sankyo; Roche Diagnostics; Menarini; : Ticagrelor, Rivaroxaban, Prasugrel, TroponinT, 
Ranolazine (2010)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca, Bayer AG,  Daiichi-Sankyo, MSD, Novartis, Sanofi-Aventis, Servie, Menarini, Roche Diagnostics, Abbott : 
Rivaroxaban, Ticagrelor, Prasugrel, Ranexa, Rasilez, (2010)
                - Astra Zeneca, Bayer Ag, Daiichi Sankyo, MSD, Novartis, Sanofi-Aventis, Servier, Roche Diagnostics : Rivaroxaban, 
Ticagrelor, Prasugrel, Ranexa, Rasilez (2011)
C - Receipt of royalties for intellectual property.
                - Roche Pharma : Troponin T  (2010)
                - Roche Pharma : Troponin T  (2011)
D - Research funding (departmental or institutional).
                - Abbottott; Medtronic; St Jude; Biotronik; : Investiagtor Initiated Trials; Clinical registries  (2010)
                - Abbott, Medtronic, St. Jude, Biotronik : Investigator Initiated Trials, Clinical registries (2011)
Levy Daniel None
Lindahl Bertil
                - Philips : Scientific advisory board for biomarkers (2010-2011)
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Lindahl Bertil B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Roche Pharma : medical advisor for clinical study (2010)
                - bioMérieux S.A : medical advisor for clinical study (2011)
                - Roche Pharma : medical advisor for clinical study and scientific advisory board (2011)
                - Philips : scientific advisory board (2011)
                - Radiometer : scientific advisory board (2011)
                - Abbott : biomarker studies (2011)
Lopez-Sendon Jose A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - BMS : Apixaban: Investigator, Committee member, Consultancy (2010-2011)
                - Merck Sharp & Dohme : Bisoprolol: Honoraria (2010-2011)
                - Boehringer-Ingelheim : Dabigatan: Committee member, Consultancy (2010-2011)
                - Sanofi Aventis : Dronedarone: Investigator, Committee member (2010)
                - GlaxoSmithKline : Investigator, Committee member (2010-2011)
                - Servier : Ivabradine: Investigator, Committee member, Consultancy, Honoraria (2010)
                - Servier : Ivabradine: Investigator, Honoraria (2011)
                - Daiichi Sankyo : Prasugrel: Investigator, Committee member, Consultancy, Honoraria (2010-2011)
                - Astra Zeneca : Ticagrelor, Rosuvastatin: Investigator, Committee member, Consultancy (2010-2011)
Luepker Russell V A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - CVRx : Malignant hypertension (2010)
                - CVRx : Neurostimulator (2011)
D - Research funding (departmental or institutional).
                - National Institutes of Health, NHLBI : Medical Research (2010)
Menasche Philippe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Edwards Lifesciences : Member of the CEC for TAVI trials (2010-2011)
                - Boston Scientific : Member of the CEC for the PLATINUM Trial (2011)
                - Regado Biosciences : Member, Medical Advisory Board (2011)
                - Regado Biosciences : Member, Medical Advosiry Board (2010)
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Menasche Philippe                 - Baxter : Member, Steering Committee, Auto-CD34+ Trial  (2011)
Mendis Shanthi None
Morrow David A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Servier : Anti-ischemic medications (2011)
                - Menarini : Anti-ischemic medications (2010)
                - Gilead : Anti-ischemic medications (2010-2011)
                - Astra Zeneca : Antithrombotic medications (2010)
                - Boehringer-Ingelheim : Antithrombotic medications (2010)
                - Johnson & Johnson : Antithrombotic medications (2011)
                - Genentech : Antithrombotic medications (2010-2011)
                - Merck Sharp & Dohme : Antithrombotic medications (2010-2011)
                - Siemens Healthcare : Diagnostic biomarkers (2010)
                - Instrumentation Laboratory : Diagnostic biomarkers (2010-2011)
                - Beckman Coulter : Diagnostic biomarkers (2010)
                - OrthoClinical Diagnostics : Diagnostic biomarkers (2010)
                - Roche Pharma : Diagnostic biomarkers (2010)
                - Critical Diagnostics : Diagnostic biomarkers (2011)
                - Roche Diagnostics : Diagnostic biomarkers (2011)
                - Novartis : Pharmaceutical remodeling (2010)
                - Ikaria : Pharmaceutical remodeling (2010)
D - Research funding (departmental or institutional).
                - Astra Zeneca : Antithrombotic medications (2010)
                - Daiichi Sankyo : Antithrombotic medications (2010)
                - Eli Lilly : Antithrombotic medications (2010)
                - Sanofi Aventis : Antithrombotic medications (2010)
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Morrow David                 - Bayer Healthcare : Antithrombotic medications (2010)
                - Merck Sharp & Dohme : Antithrombotic medications (2010)
                - Beckman Coulter : Diagnostic biomarkers (2010)
                - Siemens Healthcare : Diagnostics biomarkers (2010)
                - Singulex : Diagnostics biomarkers (2010)
                - Roche Pharma : Diagnostics biomarkers (2010)
                - GlaxoSmithKline : Lipid lowering medications (2010)
                - Novartis : Pharmaceutical remodeling (2010)
                - Astra Zeneca : Antithrombotic medications (2011)
                - Daiichi Sankyo : Antithrombotic medications (2011)
                - Eli Lilly : Antithrombotic medications (2011)
                - Sanofi Aventis : Antithrombotic medications (2011)
                - Bayer Healthcare : Antithrombotic medications (2011)
                - Merck Sharp & Dohme : Antithrombotic medications (2011)
                - Athera : Diagnostic biomarkers (2011)
                - Beckman Coulter : Diagnostic biomarkers (2011)
                - Abbott Laboratories : Diagnostic biomarkers (2011)
                - BG medicine : Diagnostic biomarkers (2011)
                - Siemens Healthcare : Diagnostics biomarkers (2011)
                - Singulex : Diagnostics biomarkers (2011)
                - Roche Pharma : Diagnostics biomarkers (2011)
                - GlaxoSmithKline : Lipid lowering medications (2011)
                - Novartis : Pharmaceutical remodeling (2011)
                - Amgen Inc : Pharmaceuticals (2011)
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Newby Kristin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Shionogi : nitroglycerin spray (2010)
                - Novartis : novel antibiotic in development (2011)
                - Daiichi Sankyo/Eli Lilly : prasugrel (2011)
                - Johnson & Johnson : rivaroxaban (2011)
                - Astra Zeneca : ticagrelor (2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Amgen Inc : cancer chemotherapeutic (2010)
D - Research funding (departmental or institutional).
                - National Institutes of Health, NHLBI : cardiovascular, molecular biology grant (2010)
                - Bristol Myers Squibb : cardiovascular--CEC APPRAISE II (2010)
                - Astra Zeneca : cardiovascular--CEC PLATO (2010)
                - Regado Biosciences : cardiovascular--CEC RADAR (2010)
                - Eli Lilly : cardiovascular--CEC TRILOGY (2010)
                - GlaxoSmithKline : cardiovascular--PI, SOLSTICE (2010)
                - Johnson & Johnson : cardiovascular--ROCKET AF biomarkers substudy (2010)
                - Amylin : diabetes, cardiovascular-- EXCEL trial biomarkers substudy (2010)
                - David H. Murdock Foundation : genomics; gift to Duke University (2010)
                - Amgen Inc : cancer chemotherapeutics (2011)
                - Amylin : exanatide (2011)
                - GlaxoSmithKline : losmapimod (2011)
                - Daiichi Sankyo : olmesartan (2011)
                - Regado Biosciences : PCI; novel anticoagulant (2011)
                - Eli Lilly : prasugrel (2011)
                - GlaxoSmithKline : rosiglitazone (2011)
                - DiaDexus : Lp-PLA2 assays (2011)
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Nieminen Markku A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Orion : Heart failure (2010)
                - DCRI : Heart Failure (2011)
                - Orionpharma : Heart Failure (2011)
                - TIMI group : Trombosis (2011)
Ohman E Magnus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Liposcience : Diagnostic tests (2010-2011)
                - WebMD : Online health information provider (2010-2011)
                - Astra Zeneca : Pharmaceuticals (2010-2011)
                - Boehringer-Ingelheim : Pharmaceuticals (2010-2011)
                - Sanofi Aventis : Pharmaceuticals (2010-2011)
                - Gilead : Pharmaceuticals (2010-2011)
                - Medicines Company : Pharmaceuticals (2010-2011)
                - Bristol Myers Squibb : Pharmaceuticals (2010-2011)
                - Merck Sharp & Dohme : Pharmaceuticals (2010-2011)
                - Pozen : Pharmaceuticals (2010-2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Daiichi Sankyo : Pharmaceuticals (2010)
                - Eli Lilly : Pharmaceuticals (2010)
D - Research funding (departmental or institutional).
                - Maquet : Medical technology/products (2010)
                - Daiichi Sankyo : Pharmaceuticals (2010)
                - Eli Lilly : Pharmaceuticals (2010)
                - Maquet : Medical technology/products (2011)
                - Daiichi Sankyo : Pharmaceuticals (2011)
                - Eli Lilly : Pharmaceuticals (2011)
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Parkhomenko Alexander A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Server : ivabradin, trimetazidin (2011)
                - Servier : Ivabradine (2010)
                - Bayer : xarelto (2011)
D - Research funding (departmental or institutional).
                - Boehringer-Ingelheim :  dabigatran (2010)
E - Research funding (personal).
                - BHFZ : corvitin (soluble ukrainian quercetin)  (2010)
                - BHFZ : corvitin (2011)
Pinto Fausto Jose A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Boehringer-Ingelheim : Dabigatran (2010-2011)
                - Servier : Ivabradine (2010)
                - Servier : Ivabradine, Perindopril (2011)
                - Astra Zeneca : Ticagrelor (2011)
                - GE Healthcare : Ultrasound equipment (2010-2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Servier : Ivabradine (2010)
                - Medtronic : CRT (2011)
                - Servier : Ivabradine (2011)
D - Research funding (departmental or institutional).
                - Servier : Ivabradine (2010)
                - GE Healthcare : Ultrasound equipment (2010)
                - Medtronic : CRT (2011)
                - Servier : Ivabradine (2011)
                - GE Healthcare : Ultrasound equipment (2011)
Ravkilde Jan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca : ADP-receptor blocker (2010-2011)
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Ravkilde Jan                 - Eli Lilly : ADP-receptor blocker (2010-2011)
Robertson Rose Marie None
Rosamond Wayne None
Simoons Maarten L A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Menarini : anti angina (2010)
                - Astra Zeneca : anti thrombotic (2010)
                - Boehringer-Ingelheim : anticoagulant (2010-2011)
Smith Sidney None
Steg Philippe Gabriel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Servier : antianginal agents (2010)
                - Bayer : anticoagulants (2010)
                - Astellas : Anticoagulants (2010)
                - Eisai : antiplatelet agent (2010)
                - Astra Zeneca : antiplatelet agents (2010)
                - Daiichi Sankyo : antiplatelet agents (2010)
                - Boehringer-Ingelheim : antithrombotics (2010)
                - Sanofi Aventis : antithrombotics (2010)
                - GlaxoSmithKline : antithrombotics (2010)
                - Medicines Company : antithrombotics (2010)
                - Bristol Myers Squibb : antithrombotics (2010)
                - Merck Sharp & Dohme : Antithrombotics (2010)
                - Pfizer : heart failure (2010)
                - Amgen : Lipid lowering treatment (2010)
                - Medtronic : stents (2010)
D - Research funding (departmental or institutional).
                - Servier : Registry on coronary artery disease (2010)
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Tendera Michal A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Bayer : Aspirin, Rivaroxaban (2010)
                - Bayer : Aspirin, Rivaroxaban (2010)
                - Amgen : Darbopoietin (2010)
                - Servier : Ivabradine, Phase II investigational products (2010)
                - TIMI group : Rivaroxaban (2010)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Servier : Ivabradine, Phase II investigational products (2010)
                - TIMI group : Rivaroxaban (2010)
Thygesen Kristian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Edwards Lifesciences : Endpoint Committee (2010-2011)
                - Servier : Endpoint Committee (2010-2011)
                - St Jude Medical : Endpoint Committee (2010-2011)
                - Roche Pharma : Endpoint Committee (2010-2011)
                - Danish Heart Foundation : Endpoint Committee (2010-2011)
                - Roche Diagnostics : Speaker fee (2011)
D - Research funding (departmental or institutional).
                - Roche Pharma : Research (2010)
                - Danish Heart Foundation : Research (2010)
                - Tryg Fonden : Research (2010)
                - Danish Heart Foundation : Research (2011)
                - Tryg Fonden : Research (2011)
                - Roche Diagnostics : Research (2011)
Underwood Stephen 
Richard
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - General Electric : Imaging (2011)
                - Covidien : Radiopharmaceuticals (2011)
                - Rapidscan Inc : regadenoson (2010)
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Underwood Stephen 
Richard
                - Rapidscan Pharma Solutions Inc : regadenoson (2011)
Uretsky Barry None
Vasilieva Elena A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - GlaxoSmithKline : Antithrombotic therapy (2010)
                - Astra Zeneca : Speaker fees (2011)
                - GlaxoSmithKline : Speaker fees (2011)
Wallentin Lars A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - BMS : Atrial fibrillation (2010-2011)
                - Boehringer-Ingelheim : Atrial fibrillation (2010-2011)
                - Pfizer : Atrial fibrillation (2011)
                - Roche Diagnostics : Biomarkers (2011)
                - GlaxoSmithKline : Coronary artery disease (2011)
                - GlaxoSmithKline : Coronary Artery Disease (2010)
                - Astra Zeneca : Myocardial infarction (2010-2011)
                - Actelion : Myocardial infarction (2010)
                - GE Healthcare : Myocardial infarction (2010)
                - Evolva : Myocardial infarction (2011)
                - Evolva : Myocardial infarction (2010)
                - Athera : Myocardial infarction (2010)
                - Athera : Myocardial infarction (2011)
                - Roche Pharma : Myocardial infarction (2010)
                - Regado Biosciences : Myocardial infarction (2010-2011)
                - Merck Sharp & Dohme : Myocardial infarction  (2011)
                - Merck Sharp & Dohme : Myocardial infarction, Atrial fibrillation (2010)
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Wallentin Lars C - Receipt of royalties for intellectual property.
                - Roche Pharma : Myocardial infarction (2010)
                - Roche Diagnostics : Myocardial infarction (2011)
D - Research funding (departmental or institutional).
                - Boehringer-Ingelheim : Atrial fibrillation (2010)
                - BMS : Atrial fibrillation, Myocardial infarction (2010)
                - GlaxoSmithKline : Coronary artery disease (2010)
                - Astra Zeneca : Myocardial infarction (2010)
                - Merck Sharp & Dohme : Myocardial infarction, Atrial fibrillation (2010)
                - BMS : Atrial fibrillation (2011)
                - Boehringer-Ingelheim : Atrial fibrillation (2011)
                - GlaxoSmithKline : Coronary artery disease (2011)
                - Astra Zeneca : Myocardial infarction (2011)
                - Merck Sharp & Dohme : Myocardial infarction (2011)
Weaver W Douglas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Medicines Company : anti paltelet drugs; Trial DSMC (2010)
                - GlaxoSmithKline : antiinschemia--Trial Steering Committee (2010)
                - Johnson & Johnson : antiplatelet drugs--Trial DSMC (2010)
                - Boston Scientific : coronary stents--Trial DSMC (2010)
                - Symetis SA : DATA and Safety Monitoring Board Clinical Trials (2011)
                - Medicines Company : DAta and safety Monitoring Board thru DCRI Clinical Trial (2011)
                - Boston Scientific : Data And Safety Monitoring Board-Clinical Trials (2011)
                - GlaxoSmithKline : Exec Comm-Clinical Trial (2011)
                - Symetis SA : valves--Trial DSMC (2010)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Bayer : anticaoagulant -DSMC (2010)
23/2713/08/2012
Universal Definition of MI (TF28) - TF Members and Additional Contributors
Expert Type of Relationship with Industry
Weaver W Douglas                 - Eli Lilly : anticoagulant--DSMC (2010)
                - Boehringer-Ingelheim : thrombolysis--Trial DSMC (2010)
White Harvey A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Regado Biosciences : Antithrombotic (2010-2011)
                - Merck Sharpe and Dohme : Diabetes (2011)
E - Research funding (personal).
                - Astra Zeneca : Antithrombotic (2010)
                - Daiichi Sankyo : Antithrombotic (2010)
                - Eli Lilly : Antithrombotic (2010)
                - Pfizer : Antithrombotic (2010)
                - Sanofi Aventis : Antithrombotic (2010)
                - GlaxoSmithKline : Antithrombotic (2010)
                - Johnson & Johnson : Antithrombotic (2010)
                - Schering-Plough : Antithrombotic (2010)
                - Medicines Company : Antithrombotic (2010)
                - Bristol Myers Squibb : Antithrombotic (2010)
                - Roche Pharma : Cholesterol (2010)
                - Merck Sharp & Dohme : Diabetes (2010)
                - National Institute for Health Research : Surgery (2010)
                - Astra Zeneca : Antithrombotic (2011)
                - Daiichi Sankyo : Antithrombotic (2011)
                - Eli Lilly : Antithrombotic (2011)
                - Pfizer : Antithrombotic (2011)
                - Sanofi Aventis : Antithrombotic (2011)
                - GlaxoSmithKline : Antithrombotic (2011)
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White Harvey                 - Johnson & Johnson : Antithrombotic (2011)
                - Schering-Plough : Antithrombotic (2011)
                - Medicines Company : Antithrombotic (2011)
                - Bristol Myers Squibb : Antithrombotic (2011)
                - Roche Pharma : Cholesterol (2011)
                - Merck Sharp & Dohme : Diabetes (2011)
                - National Institute for Health Research : Surgery (2011)
Wijns William
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Boston Scientific : device (2010)
                - Edwards Lifesciences : device (2010)
                - Terumo Inc : device (2010)
                - Cordis : device (2010)
                - Orbus Neich : device (2010)
                - Astra Zeneca : drug (2010)
                - Eli Lilly : drug (2010)
                - GlaxoSmithKline : drug (2010)
                - Bristol Myers Squibb : drug (2010)
                - Biosensors : device (2011)
                - Boston Scientific : device (2011)
                - Edwards Lifesciences : device (2011)
                - Terumo Inc : device (2011)
                - Abbott Vascular : device (2011)
                - Orbus Nech : device (2011)
                - Eli Lilly : drug (2011)
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Wijns William                 - GlaxoSmithKline : drug (2011)
                - Iroko Cardio : pharma (2011)
D - Research funding (departmental or institutional).
                - Cardio3 Biosciences : cell therapy (2010)
                - Boston Scientific : device (2010)
                - Medtronic : device (2010)
                - St Jude Medical : device (2010)
                - Biotronik : device (2010)
                - Abbott Laboratories : device (2010)
                - Therabel : drug (2010)
                - Ablynx : nano antibodies (2010)
                - Cardio3 Biosciences : cell therapy (2011)
                - Boston Scientific : device (2011)
                - Medtronic : device (2011)
                - St Jude Medical : device (2011)
                - Biotronik : device (2011)
                - Abbott Laboratories : device (2011)
                - MICELL : device (2011)
                - Therabel : drug (2011)
Wood David Allan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Roche Pharma :  Rheumatoid arthritis; Aleglitazar (2010)
                - Bayer Schering Pharma : 3rd ESC Asia CVD Symposium (2010)
                - Kowa : Atherosclerosis (2011)
                - Astra Zeneca : Crestor - Lipid Modification (2010-2011)
                - Zentiva : Generic Drug Manufacturer (2010)
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Wood David Allan                 - Merck Sharp & Dohme : Niacin - Lipid Modification (2010-2011)
                - Chugai Pharma UK : Rheumatoid arthritis (2010)
                - Pfizer : Vernicline - Smoking Cessation (2010)
D - Research funding (departmental or institutional).
                - Pfizer : Varenicline - smoking cessation (2010)
                - Pfizer : Varenicline - smoking cessation (2011)
This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines. 
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Almahmeed Wael 
Abdulrahman
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca : ACS (2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca : ACS (2011)
Arnar David O A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Medtronic : Cardiac Electronic Devices (2011)
                - Astra Zeneca : Cardiovascular Therapeutics (2011)
                - Boehringer-Ingelheim : Cardiovascular Therapeutics (2011)
                - Sanofi Aventis : Cardiovascular Therapeutics (2011)
Barili Fabio None
Bloch Kenneth None
Bolger Ann None
Botker Hans Erik None
Bozkurt Biykem
D - Research funding (departmental or institutional).
                - NIH (National Institute of Health) : DEVELOPMENT OF A LAB-ON-A-CHIP SYSTEM FOR SALIVA-BASED DIAGNOSTICS  
(2011)
Bugiardini Raffaele None
Cannon Christopher Paul A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca : Product (for CME symposium) (2011)
                - Pfizer : Product (for scientific symposium) (2011)
                - Novartis : Product (funds donated to charity) (2011)
                - Bristol Myers Squibb : Product (funds donated to charity) (2011)
                - Alnylam : Product (funds donated to charity) (2011)
C - Receipt of royalties for intellectual property.
                - Automedics Medical Systems : Product (2011)
D - Research funding (departmental or institutional).
                - Astra Zeneca : Product (2011)
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Cannon Christopher Paul                 - GlaxoSmithKline : Product (2011)
                - Takeda Pharmaceuticals : Product (2011)
                - Merck Sharp & Dohme : Product (2011)
                - Accumetrics : Product (2011)
E - Research funding (personal).
                - GlaxoSmithKline : Product (2011)
                - Merck Sharp & Dohme : Product (2011)
                - Essentialis : Product (2011)
De Lemos James A A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Sanofi Aventis : Acute Coronary Syndromes (2011)
                - Bristol Myers Squibb : Acute Coronary Syndromes (2011)
                - Astra Zeneca : consulting for acute coronary syndromes (2011)
                - Daiichi Sankyo : Endpoint committee  (2011)
E - Research funding (personal).
                - Abbott Laboratories : Biomarkers (2011)
                - Roche Diagnostics : Biomarkers (2011)
Eberli Franz Robert A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Pfizer : Atorvastatin (2011)
                - Cordis : CCVI (2011)
                - Ablynx : CEC ALX 0081 Trial (2011)
                - AGA medical : CEC PC Trial (2011)
                - Eli Lilly : Prasugrel (2011)
                - Astra Zeneca : Ticagrelor (2011)
D - Research funding (departmental or institutional).
                - St Jude Medical : Coronary and Electrophysiologic Trials (2011)
                - Biotronik : Educational Grant (2011)
                - Medtronic : Registries (2011)
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Eberli Franz Robert                 - Terumo Inc : Stent Trial (2011)
                - Abbott : Stent Trials (2011)
                - Biosensors : Stent Trials (2011)
Escobar Edgardo None
Hlatky Mark A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Medicines Company : bivalirudin (2011)
                - Gilead : ranolazine (2011)
James Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Merck Sharp & Dohme : coagulation inhibition (2011)
                - Astra Zeneca : Platelet inhibition (2011)
                - Eli Lilly : platelet inhibition (2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca : platelet inhibition (2011)
                - Eli Lilly : platelet inhibition (2011)
                - Medtronic : thrombus asp catheter (2011)
                - Terumo Inc : thrombus asp catheter (2011)
                - Vascular solutions : thrombus asp catheter (2011)
Kern Karl A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Zoll Medical : Defib, CPR and Temperature Management devices (2011)
Moliterno David A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Symetis SA : Artificial Valve (2011)
                - Boston Scientific : Stent (2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Merck Sharp & Dohme : Antithrombotic Drugs (2011)
C - Receipt of royalties for intellectual property.
                - Wiley Blackwell : Textbook (2011)
Morais Joao A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca : antiplatelets (2011)
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Morais Joao B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Bayer : anticoagulants (2011)
                - Pfizer : anticoagulants (2011)
                - Lilly : antiplatelets (2011)
                - Merck Sharp & Dohme : antiplatelets, lipid lowering (2011)
                - JaBA Recordati : hypertension (2011)
                - Servier : ischemic heart disease (2011)
Mueller Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Novartis : Acute Heart FAilure (2011)
                - BRAHMS GmbH : Diagnostics (2011)
                - Alere : Diagnostics (2011)
                - Roche Diagnostics : Diagnostics (2011)
D - Research funding (departmental or institutional).
                - Medicines Company : Acuet Heart FAilure (2011)
                - BRAHMS GmbH : Diagnostics (2011)
                - Swiss Heart Foundation : Diagnostics (2011)
                - Beckman Coulter : Diagnostics (2011)
                - Nanosphere : Diagnostics (2011)
                - Abbott Laboratories : Diagnostics (2011)
                - Roche Diagnostics : Diagnostics (2011)
Neskovic Aleksandar N A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Pfizer : Speaker fees (2011)
                - Actavis : Speaker fees (2011)
                - PharmaSwiss : speaker fees (2011)
D - Research funding (departmental or institutional).
                - Ministry of Science and Technology of the Republic of Serbia : Acute Myocardial Infarction unrestricted research grant 2011-
2015 (2011)
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Neskovic Aleksandar N E - Research funding (personal).
                - Ministry of Science and Technology of the Republic of Serbia : Acute Myocardial Infarction unrestricted research grant 2011-
2015 (2011)
Pieske Burkert Mathias A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Boehringer-Ingelheim : Anticoagulation (2011)
                - Menarini : Coronary artery disease (2011)
                - Novartis : Heart Failure (2011)
D - Research funding (departmental or institutional).
                - Medtronic : Device therapy (2011)
                - Bayer Healthcare : Heart Failure (2011)
Schulman Steven None
Storey Robert Frederick A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Medscape : Antiplatelet therapy (2011)
                - Eisai : Atopaxar (2011)
                - The Medicines Company : Cangrelor (2011)
                - Novartis : Elinogrel (2011)
                - Daiichi Sankyo : Prasugrel (2011)
                - Eli Lilly : Prasugrel (2011)
                - Astra Zeneca : Ticagrelor (2011)
                - Iroko Cardio : Tirofiban (2011)
                - Accumetrics : VerifyNow device (2011)
                - Merck Sharp & Dohme : Vorapaxar (2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Eli Lilly : Prasugrel (2011)
                - Astra Zeneca : Ticagrelor (2011)
                - Accumetrics : VerifyNow device (2011)
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Storey Robert Frederick D - Research funding (departmental or institutional).
                - Eli Lilly : Prasugrel (2011)
                - Astra Zeneca : Ticagrelor (2011)
                - Accumetrics : VerifyNow (2011)
                - Merck Sharp & Dohme : Vorapaxar (2011)
Taubert Kathryn None
Tavares Aguiar Carlos 
Manuel
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Novartis : Aliskiren, Amlodipine/Valsartan (2011)
                - Bial Portela : Amlodipine/Valsartan (2011)
                - Servier : Ivabradine (2011)
                - Daiichi Sankyo : Olmesartan, Prasugrel (2011)
                - JaBA Recordati : Pitavastatin (2011)
                - Lilly : Prasugrel (2011)
                - Astra Zeneca : Rosuvastatin (2011)
                - Bayer : Rvaroxaban (2011)
Vranckx Pascal A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Abbott : Coronary artery devices (2011)
Wagner Daniel R
D - Research funding (departmental or institutional).
                - Abbott : Stents (2011)
This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines. 
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Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Actelion : Bosentan for PAH treatment in congenital heart disease (2010-2011)
                - AGA : Devices for catheter treatment of congenital heart defects (2010)
                - Edwards Lifesciences : transcatheter valve implantation (2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Edwards Lifesciences : transcatheter valve implantation (2010)
                - Actelion : Bosentan for PAH treatment in congenital heart disease (2011)
                - Edwards Lifesciences : transcatheter valve implantation (2011)
Bax Jeroen
                - Heart.org : Education (2010)
                - Astra Zeneca : Farma (2010)
                - Servier : Farma (2010)
                - Philips : Imaging (2010)
                - GE Healthcare : Imaging (2010)
                - Lantheus Inc : Imaging (2010)
                - Boston Scientific : Pacing (2010)
                - Medtronic : Pacing (2010)
                - St Jude Medical : Pacing (2010)
                - Biotronik : Pacing (2010)
                - Impulse Dynamics : Pacing (2010)
D - Research funding (departmental or institutional).
                - Servier : Farma (2010)
                - Edwards Lifesciences : Heart Valves (2010)
                - GE Healthcare : Imaging (2010)
                - Lantheus Inc : Imaging (2010)
                - Boston Scientific : Pacing (2010)
                - Medtronic : Pacing (2010)
                - St Jude Medical : Pacing (2010)
                - Biotronik : Pacing (2010)
                - Servier : Farma (2011)
                - Edwards Lifesciences : Heart Valves (2011)
                - GE Healthcare : Imaging (2011)
                - Lantheus Inc : Imaging (2011)
                - Boston Scientific : Pacing (2011)
13/08/2012 2/16 
ESC Committee for Practice Guidelines  2010-2012
Expert Type of Relationship with Industry
 
                - Medtronic : Pacing (2011)
                - St Jude Medical : Pacing (2011)
                - Biotronik : Pacing (2011)
Ceconi Claudio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Servier : Pharmaceutical (2010-2011)
Deaton M Christi
                - St Jude Medical : Cath lab - speaker X 1 (2010)
                - Daiichi Sankyo : consultant for patient adherence 2009-10 (2010)
                - Eli Lilly : consultant for patient adherence 2009-10 (2010)
D - Research funding (departmental or institutional).
                - Novo-Nordisk : medicines for diabetes  (2010)
                - Novo-Nordisk : patients with heart failure and diabetes (2011)
Fagard Robert A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Servier : Honorarium for manuscript (2011)
                - Servier : Honorarium for manuscript in Medicographia (2010)
Funck-Brentano Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Novartis CH : Adjudication Committee on an immunosuppressant (2011)
                - Lundbeck : Cardiac safety of an antidepressant (2011)
                - Pierre-Fabre : Cardiac Safety of non-cardiovasclar products (2010-2011)
                - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2010-2011)
                - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. 
                - MMV (CH) : Cardiac Saftey of an antimalarial drug (2010-2011)
                - Santhera (CH) : Cardiac Saftey of an antimalarial drug (2010-2011)
                - Sigma Tau : Cardiac Saftey of an antimalarial drug (2010-2011)
                - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety (2010-2011)
                - CEPHALON : DSMB in an oncology phase IIb trial (2010-2011)
                - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel (2010-2011)
                - Intracellular Therapies USA : Psyhotropic drug developement (2011)
D - Research funding (departmental or institutional).
                - Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel (2010)
Hasdai David A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Sanofi Aventis : Enoxaparin (2010)
                - Boehringer-Ingelheim : Pradaxa (2011)
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                - Bayer : Rivaroxiban (2011)
                - Astra Zeneca : Ticagrelor (2011)
                - Eli Lilly : Effient (2011)
Hoes Arno
                - Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips 
                - Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from 
D - Research funding (departmental or institutional).
                - Bayer Healthcare : unresctricted grant for diagnostic kits in suspected cardiovascualar disease  (2010)
                - Abbott Laboratories : unresctricted grant for diagnostic kits in suspected cardiovascualar disease  (2010)
                - Roche Pharma : unresctricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome (2010)
                - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We 
perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addi : I chair 
a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and 
industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff 
receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not 
to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2011)
Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - BMS : cardiovascular (2011)
                - Boehringer-Ingelheim : cardiovascular (2011)
                - Daiichi Sankyo : cardiovascular (2011)
                - Medtronic : cardiovascular (2011)
                - St Jude Medical : cardiovascular (2011)
                - Sanofi Aventis : cardiovascular (2011)
                - Meda pharma : cardiovascular (2011)
                - Merck Sharp & Dohme : cardiovascular (2011)
                - Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2011)
D - Research funding (departmental or institutional).
                - St Jude Medical : cardiovascular (2011)
                - Sanofi Aventis : cardiovascular (2011)
                - Meda pharma : cardiovascular (2011)
Knuuti Juhani A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Lantheus Inc : Imaging tracers (2010)
                - Lantheus Inc : Perfusion imaging tracer development (2011)
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D - Research funding (departmental or institutional).
                - Bayer : Development of imaging agents (2010)
                - Novartis : Development of imaging agents (2010)
                - GE Healthcare : Development of imaging agents (2010)
                - Lantheus Inc : Development of imaging agents (2010)
                - Roche Pharma : Drugs for brain diseases (2010)
                - Astra Zeneca : Neurology (2011)
                - GE Healthcare : Neurology and molecular imaging (2011)
Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Merck Sharp & Dohme : Antiarrhythmic agents (2010)
                - Merck Sharp & Dohme : Antiarrythmic agents (2011)
                - Astra Zeneca : Antiplatelet agents (2010-2011)
                - Bristol Myers Squibb : Antiplatelet agents (2010)
                - Regado Biosciences : Antithrombotic agents (2010-2011)
                - Abbott : coronary stents (2010)
                - Abbott Vascular : Coronary stents (2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Merck Sharp & Dohme : Antistaphylococcic vaccine (2010)
                - Merck Sharp & Dohme : Antistaphylococcic vaccine (2011)
D - Research funding (departmental or institutional).
                - Edwards Lifesciences : Cardiac valves (2010)
                - Medtronic : Cardiac valves (2010)
                - St Jude Medical : Cardiac valves (2010)
                - Siemens Healthcare : Imaging (2010)
                - Johnson & Johnson : Thoracoscopic devices (2010)
                - Edwards Lifesciences : Cardiac valves (2011)
                - Medtronic : Cardiac valves (2011)
                - St Jude Medical : Cardiac valves (2011)
                - Boston Scientific : Coronary stents (2011)
                - Siemens Healthcare : Medical imaging (2011)
                - Johnson & Johnson : Thoracoscopic devices (2011)
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McDonagh Theresa A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Vifor International : Ferrinject (2010-2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Servier : Ivabridine (2010)
                - Servier : Ivabridine (2011)
D - Research funding (departmental or institutional).
                - Biotronik : CRT (2010)
Popescu Bogdan Alexandru A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - GE Healthcare : Imaging (2010-2011)
Reiner Zeljko A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Bayer : anticoagulants (2011)
                - Bayer Healthcare : anticoagulants (2010)
                - Abbott : antilipemics (2010)
                - Astra Zeneca : antilipemics (2010-2011)
                - Pfizer : antilipemics (2010-2011)
                - Sanofi Aventis : antilipemics (2011)
                - Abbott Laboratories : antilipemics (2011)
                - Merck Sharp & Dohme : antilipemics (2010)
                - Merck Sharp & Dohme : antilipemics (2011)
Sechtem Udo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Boehringer-Ingelheim : Anticoagulation (2010-2011)
                - Daiichi Sankyo : Antiplatelet therapy (2010)
                - Novartis : Drugs (2010-2011)
                - Pfizer : Drugs (2011)
                - Siemens Healthcare : Imaging (2010)
                - General Electric : Imaging (2010)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Novartis : Imaging devices (2010)
                - Johnson & Johnson : Stents (2010)
                - Novartis : Drugs (2011)
                - Johnson & Johnson : Stents (2011)
Sirnes Per Anton
13/08/2012 6/16 
ESC Committee for Practice Guidelines  2010-2012
Expert Type of Relationship with Industry  
D - Research funding (departmental or institutional).
                - Bayer : clinical studies  atrial fibrillation  investigator fee (ROCKET) (2010)
                - Merck Sharp & Dohme : investgator fee clinical  studies hyperlipidemia, SCAD (THRIVE) (2010)
                - GlaxoSmithKline : investigator fee, clinical study  , SCAD (2010)
                - Sanofi Aventis : investigator fee, clinical study (PALLAS) (2010)
                - Servier : investigator fee, clinical study, coronary  artery disease (SIGNIFY) (2010)
                - Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2010)
                - Boehringer-Ingelheim : investigator fee, clinicla study, AF (RELY. RELYABLE) (2010)
                - Merck Sharp & Dohme : investgator fee clinical  studies hyperlipidemia, SCAD (THRIVE) (2011)
                - GlaxoSmithKline : investigator fee, clinical study  , SCAD (2011)
                - Servier : investigator fee, clinical study, coronary  artery disease (SIGNIFY) (2011)
                - Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2011)
Tendera Michal A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Bayer : Aspirin, Rivaroxaban (2011)
                - Amgen : Darbopoietin (2011)
                - Servier : Ivabradine, Phase II investigational products (2011)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Servier : Ivabradine, Phase II investigational products (2011)
                - TIMI group : Rivaroxaban (2011)
Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Boehringer-Ingelheim : anticoagulation (2010)
                - Sanofi Aventis : anticoagulation (2010)
                - Pfizer : anticoagulation, pulmonary hypertension (2010)
                - United Therapeutics : Pulmonary arterial hypertension (2011)
                - GSK : pulmonary arterial hypertension - ambrisentan (2011)
                - Actelion : pulmonary arterial hypertension - macisentan, selexipag (2011)
                - Lilly : pulmonary arterial hypertension - tadalafil (2011)
                - AOP : Pulmonary arterial hypertension - treprostinil (2011)
                - Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat (2011)
                - Actelion : pulmonary hypertension (2010)
                - Lilly : pulmonary hypertension (2010)
                - Bayer Healthcare : pulmonary hypertension, anticoagulation (2010)
                - Bristol Myers Squibb : thromboembolic disease - Apixaban (2011)
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                - Bayer Healthcare : Pulmonary hypertension (2011)
                - Sanofi Aventis : Thromboembolic disease (2011)
Vahanian Alec A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Abbott : valve disease (2011)
                - Valtech : valve disease (2011)
                - Medtronic Foundation : valve disease (2011)
                - saint Jude medical : valve disease (2011)
                - Edwards Life sciences : valve disease (2011)
                - Abbott : Valve prostheses (2010)
                - Boehringer-Ingelheim : Valve prostheses (2010)
                - Edwards Lifesciences : Valve prostheses (2010)
                - Medtronic : Valve prostheses (2010)
                - Valtech : Valve prostheses (2010)
                - Siemens Healthcare : Valve prostheses (2010)
Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.
                - Astra Zeneca : Antiplatelet drug (2010-2011)
                - Eli Lilly : Antiplatelet drug (2010-2011)
                - Abbott : Stent (2010-2011)
                - Biosensors : Stent (2010-2011)
                - Boston Scientific : Stent (2010-2011)
                - Medtronic : Stent (2010-2011)
                - Biotronik : Stent (2010-2011)
                - Cordis : Stent (2010-2011)
D - Research funding (departmental or institutional).
                - Abbott : Stent (2010)
                - Biosensors : Stent (2010)
                - Medtronic : Stent (2010)
                - Cordis : Stent (2010)
                - St Jude Medical : OCT (2011)
                - Abbott : Stent (2011)
                - Biosensors : Stent (2011)
                - Medtronic : Stent (2011)
                - Biotronik : Stent (2011)
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This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines. 
                - Cordis : Stent (2011)
